Rein therapeutics to present novel ipf science and clinical development insights at ipf summit 2025

Austin, texas, aug. 14, 2025 (globe newswire) -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that chief scientific officer, cory hogaboam, and chief executive officer, brian windsor, will each present at the ipf summit 2025, taking place august 19-21, 2025, in boston, ma. dr. hogaboam will present at 8:00 am on tuesday in a workshop titled, “decoding the disruptions in natural biological processes to advance early intervention in ipf – unravelling the molecular biology of immune cells & inflammation.
RNTX Ratings Summary
RNTX Quant Ranking